Specialist Biometrics CRO, Veramed, today announced the acquisition of Boston-based biometrics, rescue and submission specialists, BioPier. This acquisition will elevate Veramed’s global presence and broaden the company’s capabilities. By combining their extensive knowledge, experience, and commitment, this deal will help to strengthen Veramed’s agility to provide best-in-class biometrics services and accelerate the development of life-changing medicines for patients around the world.
Quality is at the heart of everything Veramed does, and this can only be ensured through a combination of the right practices, processes, and people. The shared vision of Veramed and BioPier will drive more effective, efficient biometrics that accelerates the pace of groundbreaking medical developments that could further enhance patient outcomes.
Matt Jones, Co-Founder and CEO of Veramed, commented “I’m delighted to be welcoming Lixin and the BioPier team into the Veramed community. Our two companies not only share a commitment to quality and specialist excellence, but also a deep desire to deliver a meaningful impact within our industry. Working together, we will raise the bar on speed, responsiveness, and agility for biometrics services, and help to accelerate the research and development of new, life-changing medicines”.
Lixin Gao, Founder and President at BioPier, commented “After spending the last 18 years building and serving top-name biopharma companies, we were looking for a true partnership that reflects our core values: delivering services on time and with top quality and keeping our employees with us for the long haul. From our very first meeting with Veramed, the highly respected CRO led by Matt and Emma, I felt an incredible synergy between our teams. We’re really excited to become part of the Veramed community and are looking forward to working together to provide our clients with world-class biometrics services”.
About Veramed
Veramed is a high-performing partner for statistical consultancy, data management, clinical trial reporting and automation, DMC services, and evidence and value generation. Veramed is a pioneering CRO that is redefining intelligent healthcare decision-making. The talented Veramed team offers pharma and biotech clients flexible, tailored biometrics solutions that scale and adapt along with the needs of their organization, from initial study design to submission and beyond. Veramed is also known for taking up industry-leading involvement in projects such as the recent PHUSE/CDISC Dataset-JSON initiative.
Veramed is uniquely practitioner-led, and passionate about making a difference to patient communities around the world by moving the needle on the speed, quality and effectiveness of pharma and biotech pipeline delivery.
Veramed was awarded “Best Contract Research Organization – Specialist Providers” at the 18th Annual Scrip Awards in 2022 and certified as a B Corp for the first time in 2020. For more details, see the Veramed website at: https://www.veramed.com/
About BioPier
BioPier Inc. is a Boston-based premium contract research organization (CRO) specializing in biostatistics and programming. Established by Lixin Gao in 2006 to revolutionize clinical data review and biostatistical analysis in drug development. BioPier is recognized for its quality, on-time delivery, and experienced and efficient handling of drug submissions, particularly its capability to manage and accelerate urgent projects. The company takes pride in its extensive end-to-end biometrics expertise and proven track record of successful drug submissions. Trusted by leading biopharma companies, BioPier has conducted over 150 clinical study analyses in challenging therapeutic areas such as oncology, rare diseases, gastroenterology, vaccines, and more. Its decade-long service has contributed to the approval of more than 15 of the most innovative drugs, biologics, and medical devices for the betterment of patient health outcomes.
